Secondary Use Pharmaceutical Patents: Litigation and Trade Policy Briefing
Sponsored by PIJIP and Public Citizen’s Global Access Campaign
Hosted by Sterne Kessler, Goldstein & Fox
June 5, 2014
This event’s first panel discussed the recent case that Eli Lilly has brought against the Canadian government under NAFTA, in which Lilly alleges that Canada improperly denied patent protection for two drugs based on its “promise doctrine.” The second panel explored the issues more broadly, focusing on differences in U.S., Canadian, and European practices relating to the patenting of pharmaceutical products.
Panel 1: Eli Lilly and the Canadian NAFTA Challenge
- Padideh Ala’i, American University Washington College of Law, Moderator
- Sean Flynn, American University Washington College of Law
- Burcu Kilic, Public Citizen
- Simon Lester, Cato Institute
- Andrew Williams, MBHB
11:15 – 12:30 Panel 2: Secondary Use Patents: A Comparative View
- Jorge Contreras, American University Washington College of Law, Moderator
- John Covert, Sterne Kessler
- Richard Gold, McGill University
- Jonathan Stainsby, Aiken & Klee
- Norman Siebrasse, University New Brunswick
See also: Public Citizen Global Access to Medicines write up of the event
